RE:Copilot: potential benefits of avenanthramide "The safety and bioavailability study will evaluate avenanthramides as a stand-alone therapy or potentially in combination with carriers recently developed using our PGX technology to address some inflammation-based diseases, which we believe shows great promise.” Aug. 4, 2020
We've never seen promising data combining CZO's avenanthramide with a newer generation PGX carrier. That's top secret and Gilles is a man with a long-term plan with Ronnie Miller by his side and "thrilled". The merger with AEZS and clinical trial results with the pill could allow next-gen formulation of avenanthramide with PGX to move forward further strengthening the scientific claims in large markets.